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The Integrative Clinical Nutrition Dialysis Score is a new quantitative
method for identifying nutritional risk in hemodialysis patients. It is based
on biochemical measures and weight change taken as a part of the patient’s
monthly routine care and can be accomplished within a short time
following completion of laboratory results. The Scoring result is a number
between 0-100 given for each patient. A higher Score indicates a good
nutritional status, a lower Score represents malnutrition. The Score
identiﬁes also a monthly change in nutritional status, and patients who
should receive nutritional intervention. In 59 patients, Score results were
found to be signiﬁcantly correlated with nutrition evaluation by the
Subjective Global Assessment taken within the same month. In 165
patients, baseline score emerged as a signiﬁcant inverse predictor of
mortality and hospitalization: each 1-unit increase in score reduced
mortality risk by 7.1%, and reduced hospitalization risk by 6.5%. A 1- unit
increase of slope of monthly scores reduced mortality risk by 23.6% and
reduced hospitalization risk by 20.1%. A threshold of Score greater or equal
to 75 reduced mortality by 64.2%. Patients were divided into four
categories based on baseline score (above/equal or below a threshold of 75)
and slope of monthly scores (smaller or larger/equal to 0). Worsening
nutrition status over time as indicated by both score and slope, signiﬁcantly
increased death hazard. Results conﬁrm that Integrative Clinical Nutrition
Dialysis Score (ICNDS) is a simple, useful prognostic tool to reﬂect
hemodialysis patients nutrition status, and nutrition deterioration at its
very commencement.
http://dx.doi.org/10.1016/j.krcp.2012.04.626
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Peginesatide (P) is a synthetic, pegylated, peptide-based ESA approved
for treatment of anemia due to chronic kidney disease in adult patients
(pts) on dialysis. P demonstrated noninferiority to epoetin (E) in
maintenance of Hb levels in hemodialysis (HD) pts in two Phase
3 randomized, active-controlled, open-label trials (EMERALD 1,2). A large
dialysis organization (LDO) recently reported an ESA dose adjustment rate
of 12.1/pt-year (Bond et al, ISPOR 2012). This post hoc analysis evaluated
dosing practices for maintaining Hb with P vs E.
Pooled data from the two trials compared P (1x monthly; N¼1066) with
E (1-3x wkly; N¼542) in HD pts previously on stable doses of E. Hb was
measured during screening, at baseline and wkly (evaluation period, wks
29-36) or every 2 wks (all other periods). Dose adjustments were not to be
made more frequently than every 4 wks, unless required for safety
purposes. Dose adjustments (deﬁned as change 4720% from last dose)
were evaluated during the titration (wks 0-28), evaluation, and long-term
follow-up (LT, wks 36-52) periods. Dose postponements were deﬁned as
435d for P; for E, they were 44d, 6d, or 9d for TIW, BIW, and QW,
respectively.
Across the entire study period, P doses were adjusted 3 times less
frequently and held 8 times less than P (Table).
P (per pt-year) E (per pt-year) E/P ratio
Total Dose Adjustments 3.5 10.3 2.9
Dose Increases 1.7 5.3 3.0
Dose Decreases 1.8 5.0 2.8
Dost Postponements 0.6 5.0 8.3
Within each treatment arm, dose adjustment and postponement rates
(including corresponding E/P ratios) were similar across titration,
evaluation, and LT periods.
E dose adjustment rate was similar to that of real world practice in an
LDO. E doses were adjusted and held more frequently than P despite
similar protocol speciﬁcations for dose alteration and Hb maintenance.
http://dx.doi.org/10.1016/j.krcp.2012.04.627
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Recent post hoc analyses of large randomized clinical trials have
suggested an association between high ESA dose and cardiovascular events
(Szczech et al. 2008 KI 74:791). In 2011, implementation of CMS ESRD
bundled payment and FDA-mandated ESA label changes that target lower
hemoglobin (Hb) created further downward pressure on ESA doses. Long-
term safety of intravenous (IV) iron is poorly understood. This study
evaluated temporal changes in the ratio of IV iron-to-epoetin use across
patients (N¼200,170) from a large dialysis organization from 2008
through 2011.
Mean IV iron use was normalized to mg/month. Mean epoetin was
normalized to U/month. The IV iron-to-epoetin ratio was calculated by
taking the mean IV iron value relative to mean epoetin (per 1000U/month)
for Q1 2008 – Q4 2011.
Although mean epoetin utilization has fallen since start of Q3 2010,
mean IV iron utilization has remained fairly stable. From Q1 2008 to Q3
2010, the ratio of IV iron-to-epoetin was constant (2.5 mg/month for every
1000 U per month), but has risen 46% from Q3 2010 to Q4 2011, while
hemoglobin levels have fallen 0.9 g/dL (11.5 to 10.6 g/dL).
While ESA doses decreased, iron doses remained constant, resulting in a
shift toward a higher ratio of iron-to-ESA use from Q3 2010 through Q4
2011. Further analyses are warranted to understand the appropriate
balance between iron and ESA use with regards to efﬁcacy and safety
http://dx.doi.org/10.1016/j.krcp.2012.04.628
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On average ESRD patients are hospitalized twice yearly for 12 days a year
(USRDS 2011 Ann. Report). Hb levels decline immediately post-
hospitalization, requiring extended periods for recovery and elevated ESA
dosing for 41 year (Solid et al. Hemodial Int. 2007). We evaluated post-
hospitalization anemia trends and ESA use in ESRD.
Data from an LDO (N¼273,877 pts; Q1 2008–Q1 2011) were evaluated
for post-hosp Hb change (difference, pre- and post-hosp Hb measurement),
time to Hb recovery (time from discharge to when Hb levels Z pre-hosp
level), time to ESA recovery (time from discharge until 3 consecutive non-
zero epoetin doses r pre-hosp dose) and incremental ESA (sum of all
differences from last pre-hosp dose until ESA recovery, 6 months if no
recovery, or end of follow-up for long-term follow-up population).
62% of all hospitalizations were associated with declining Hb (mean, -
1.29 g/dL; Figure); 54% of these never returned to pre-hosp levels. Among
hospitalizations that experienced a Hb drop and eventually recovered Hb
(mean recovery time, 42 days), 73% used a mean 56K U of incremental
epoetin until recovery; dose was recovered within 68 days on average. For
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